Prescribing Information

Home / Efficacy / Patient Profiles

Plan early for TECARTUS® in your adult patients with R/R B-cell ALL

Patients who relapse following allo-SCT need a different treatment approach1

Headshot of a female representing TECARTUS® patient.
Initial Diagnosis

38-year-old female with Ph-negative B-cell acute lymphoblastic leukemia

ECOG PS: 0

Key pathology and diagnostic test results
  • Immunohistochemistry: CD19+, CD20-, and CD22+
  • BM biopsy: 35% blasts
Treatment History
Newly diagnosed ALL Induction:
  • CALGB 10403 regimen
    – Achieved MRD-positive CR
Consolidation:
  • Blinatumomab
    – Achieved MRD-negative CR
  • Allo-SCT
Results:
  • Patient achieved MRD-negative status following consolidation and relapsed at 13 months post allo-SCT

Consider TECARTUS for your adult patients with R/R B-cell precursor ALL who relapse following allo-SCT

Following first relapse, patients face poor outcomes2

Headshot of a male representing TECARTUS® patient.
Initial Diagnosis

58-year-old male with Ph-negative B-cell acute lymphoblastic leukemia

ECOG PS: 1

Key pathology and diagnostic test results
  • Immunohistochemistry: CD19+, CD20+, and CD22+
  • BM biopsy: 67% blasts
Treatment History
Newly diagnosed ALL Induction:
  • Hyper-CVAD

    –  Achieved MRD-positive CR

Consolidation and maintenance:
  • Hyper-CVAD continuation
  • Oral POMP for 24 months
Results:
  • Patient achieved MRD-negative status in CR1; relapsed at 36 months after initial diagnosis with high disease burden (60% blasts)
First relapse Treatment:
  • Inotuzumab ozogamicin

    –  Achieved MRD-negative CR

Results:
  • Patient achieved MRD-negative status in CR2; did not receive allo-SCT due to donor unavailability. Patient relapsed at 5 months

Consider TECARTUS for your adult patients who relapse or are refractory to SOC therapy

For adults with R/R B-cell ALL, plan for CAR T‐cell therapy

Educate patients about CAR T-cell therapy

Determine eligibility for future CAR T treatment

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; BM=bone marrow; CALGB 10403 regimen=daunorubicin, vincristine, prednisone, and pegaspargase; CAR=chimeric antigen receptor; CD=cluster of differentiation; CR=complete remission; CR1=first complete remission; CR2=second complete remission; ECOG PS=Eastern Cooperative Oncology Group performance status; hyper-CVAD=hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; MRD=minimal residual disease; Ph=Philadelphia chromosome; POMP=methotrexate, 6-mercaptopurine, vincristine, and prednisone; R/R=relapsed or refractory; SOC=standard of care.

References: 1. Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-1533. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 4, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.

Up next: Overall Safety Profile >